

HE Dr Stela Grigoras
The Minister of Health, Labour and Social Protection
Ministry of Health, Labour and Social Protection
2, Alexandri Str.
MD-2009 Chisinau
The Republic of Moldova

13 December 2017

Decision Letter: Request for 2018 Renewal of Gavi support for Inactivated Polio Vaccine

Your Excellency,

I am writing in relation to Moldova's request for renewal of the New Vaccine Support (NVS) for Inactivated Polio Vaccine that was reviewed by the Gavi Secretariat on 25 October 2017.

Following the recommendations made by the Gavi Secretariat review, I am pleased to inform you that Gavi has **approved** Moldova's request to renew Gavi support for Inactivated Polio Vaccine for 2018, subject to several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

Appendix A: Moldova Support for Inactivated Polio Vaccine (IPV)

Appendix B: Moldova Support for Injection Safety Devices

Please do not hesitate to contact my colleague Ms Jamilya Sherova, Senior Country Manager for Moldova, at jsherova@gavi.org if you have any questions or concerns.

Yours sincerely,



Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
The EPI Manager
WHO Country Representative
UNICEF Country Representative
Regional Working Group
WHO HQ
UNICEF Programme Division
UNICEF Supply Division

**Decision Letter
Moldova - Support for Inactivated Polio Vaccine (IPV)**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Moldova			
2. Grant number: 1518-MDA-25d-X/15-MDA-08h-Y			
3. Date of Decision Letter: 13/12/2017			
4. Date of the Partnership Framework Agreement: 05/02/2015			
5. Programme title: New Vaccine Support, Inactivated Polio Vaccine, routine			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 1 dose per vial, LIQUID			
8. Programme duration²: 2015 - 2018			
9. Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement) <i>Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2017	2018	Total³
Routine Programme (US\$)	4,541 ⁴	127,500	132,041
10. Vaccine introduction grant / Product switch grant: US\$100'000 disbursed on 18 th March 2015.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁵			
Number of vaccines to be purchased with Gavi funds	2015-2017	2018	
IPV Routine Programme (doses)		43,400	
Annual Amounts (US\$)	4,541	127,500	
12. Procurement agency: UNICEF.			
13. Self-procurement: Not applicable.			
14. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Moldova is encouraged to contribute to vaccine and/or supply costs for IPV.			
15. Operational support for catch-up campaigns: Not applicable			
16. Additional reporting requirements:			
Reports and other information	Due dates		
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May		

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for 2015 to 2018.

⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁵ This is the amount that Gavi has approved.

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
18. Other conditions: Not applicable. <p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p> <p>If Moldova envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Moldova.</p>	

Signed by



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

13 December 2017

**Decision Letter
Moldova - Support for Injection Safety Devices**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Moldova			
2. Grant number: 17-MDA-32a-X; 18-MDA-32a-X			
3. Date of Decision Letter: 13/12/2017			
4. Date of the Partnership Framework Agreement: 05/02/2015			
5. Programme title: Injection safety devices ⁶			
6. Programme duration⁷: 2017-2018			
7. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2017	2018	Total⁸
Programme Budget (US\$)	3,500	2,000	5,500
8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁹			
TOTAL injection safety devices to be purchased with Gavi funds in each year	2017	2018	
Number of AD syringes			33,000
Number of re-constitution syringes			
Number of safety boxes			375
Annual Amounts for injection safety devices for all Gavi vaccines (US\$)	3,500	2,000	
Injection safety devices to be purchased with Gavi funds in each year, by type of support			
New Vaccine Support (NVS), HPV Quadrivalent, 1 dose per vial, LIQUID, Demonstration			2018
Number of AD syringes			33,000
Number of re-constitution syringes			0
Number of safety boxes			375
Annual Amounts for injection safety devices for Vaccine (US\$)			2,000
9. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
10. Self-procurement: Not applicable.			
11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter.			

Signed by



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
13 December 2017

⁶ This does not include vaccines.

⁷ This is the entire duration of the Programme.

⁸ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁹ This is the amount that Gavi has approved.